{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:25:36Z","timestamp":1787027136124,"version":"build-2736575974"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Elexacaftor-Tezacaftor-Ivacaftor (ELE\/TEZ\/IVA) is believed to be an effective and well-tolerated treatment for cystic fibrosis (CF), but the exact efficacy and safety profile are still unknown.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    This study aimed to clarify the extent of functional restoration when patients are given with triple combination treatment and demonstrate the prevalence of adverse events, to evaluate the overall profile of ELE\/TEZ\/IVA on CF.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A literature search was conducted in PubMed, Web of Science and Cochrane Library. Random effects single-arm meta-analysis was performed to decipher the basal characteristics of CF, the improvement and safety profile after ELE\/TEZ\/IVA treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total 53 studies were included in this analysis. For all the patients in included studies. 4 weeks after ELE\/TEZ\/IVA treatment, the increasement of percentage of predicted Forced Expiratory Volume in the first second (ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    ) was 9.23% (95%CI, 7.77%\u201310.70%), the change of percentage of predicted Forced Vital Capacity (ppFVC) was 7.67% (95%CI, 2.15%\u201313.20%), and the absolute change of Cystic Fibrosis Questionnaire\u2013Revised (CFQ-R) score was 21.46 points (95%CI, 18.26\u201324.67 points). The Sweat chloride (SwCl) was significantly decreased with the absolute change of \u221241.82\u00a0mmol\/L (95%CI, \u221244.38 to \u221239.25\u00a0mmol\/L). 24 weeks after treatment, the increasement of ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    was 12.57% (95%CI, 11.24%\u201313.90%), the increasement of ppFVC was 10.44% (95%CI, 7.26%\u201313.63%), and the absolute change of CFQ-R score was 19.29 points (95%CI, 17.19\u201321.39 points). The SwCl was significantly decreased with the absolute change of \u221251.53\u00a0mmol\/L (95%CI, \u221256.12 to \u221246.94\u00a0mmol\/L). The lung clearance index\n                    <jats:sub>2.5<\/jats:sub>\n                    (LCI\n                    <jats:sub>2.5<\/jats:sub>\n                    ) was also decreased by 1.74 units (95%CI, \u22122.42 to \u22121.07 units). The body mass index increased by 1.23\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (95%CI, 0.89\u20131.57\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ). As for adverse events, 0.824 (95%CI, 0.769\u20130.879) occurred during ELE\/TEZ\/IVA period, while the incidence of severe adverse events was 0.066 (95%CI, 0.028\u20130.104).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    ELE\/TEZ\/IVA is a highly effective strategy and relatively safe for CF patients and needs to be sustained to achieve better efficacy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    Identifier: CRD42023441840.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1275470","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T08:32:49Z","timestamp":1702542769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Wenye","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jcf.2020.05.004","article-title":"Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor\/ivacaftor compared to males","volume":"20","author":"Aalbers","year":"2021","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/thoraxjnl-2012-202552","article-title":"Longitudinal association between lung function and health-related quality of life in cystic fibrosis","volume":"68","author":"Abbott","year":"2013","journal-title":"Thorax"},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1125853","DOI":"10.3389\/fphar.2023.1125853","article-title":"Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor\/tezacaftor\/ivacaftor therapy in patients with cystic fibrosis-a real world study","volume":"14","author":"Appelt","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","article-title":"Modulators of CFTR. Updates on clinical development and future directions","volume":"213","author":"Bardin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.7326\/M22-1741","article-title":"Challenged urine bicarbonate excretion as a measure of cystic fibrosis transmembrane conductance regulator function in cystic fibrosis","volume":"175","author":"Berg","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1172\/JCI115450","article-title":"Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel","volume":"88","author":"Berger","year":"1991","journal-title":"J. Clin. investigation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"Bermingham","year":"2021","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: a 48-Week Observational Study","volume":"11","author":"Carnovale","year":"","journal-title":"J. Clin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic Fibrosis Patients with F508del\/Minimal Function Genotype: laboratory and Nutritional Evaluations after One Year of Elexacaftor\/Tezacaftor\/Ivacaftor Treatment","volume":"11","author":"Carnovale","year":"","journal-title":"J. Clin. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2200725","DOI":"10.1183\/13993003.00725-2022","article-title":"Elexacaftor\/tezacaftor\/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis","volume":"61","author":"Cavinato","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/s0022-3476(97)70025-8","article-title":"Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis","volume":"131","author":"Corey","year":"1997","journal-title":"J. Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1073\/pnas.88.20.9262","article-title":"Immunocytochemical localization of the cystic fibrosis gene product CFTR","volume":"88","author":"Crawford","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100307","DOI":"10.1016\/j.jcte.2022.100307","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in cystic fibrosis: a review","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr. Clin. Pract. official Publ. Am. Soc. Parenter. Enter. Nutr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ppul.20054","article-title":"Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis","volume":"38","author":"Davis","year":"2004","journal-title":"Pediatr. Pulmonol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1513\/AnnalsATS.202102-220RL","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in advanced cystic fibrosis lung disease","volume":"18","author":"Djavid","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/Ivacaftor in Subjects with Cystic Fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1378\/chest.12-1430","article-title":"Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience","volume":"143","author":"Durmowicz","year":"2013","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcf.2017.11.002","article-title":"The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype","volume":"17","author":"Espel","year":"2018","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV(1) in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcf.2022.01.007","article-title":"Measuring the effect of elexacaftor\/tezacaftor\/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography","volume":"21","author":"FitzMaurice","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.rmed.2014.03.011","article-title":"Tracking Lung Clearance Index and chest CT in mild cystic fibrosis lung disease over a period of three years","volume":"108","author":"Fuchs","year":"2014","journal-title":"Respir. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcf.2021.07.006","article-title":"Response to elexacaftor\/tezacaftor\/ivacaftor in intestinal organoids derived from people with cystic fibrosis","volume":"21","author":"Furstova","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"d1008","DOI":"10.1136\/bmj.d1008","article-title":"Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007","volume":"342","author":"George","year":"2011","journal-title":"BMJ Clin. Res. ed)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.3390\/jcm11206160","article-title":"Dynamic perfluorinated gas MRI shows improved lung ventilation in people with cystic fibrosis after elexacaftor\/tezacaftor\/ivacaftor: an observational study","volume":"11","author":"Goralski","year":"2022","journal-title":"J. Clin. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcf.2021.05.002","article-title":"Overweight and obesity in adults with cystic fibrosis: an Italian multicenter cohort study","volume":"21","author":"Gramegna","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and potentiators rescue function of the truncated W1282x-cystic fibrosis transmembrane regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet (London, Engl."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1378\/chest.13-1320","article-title":"Understanding the relationship between sweat chloride and lung function in cystic fibrosis","volume":"144","author":"Heltshe","year":"2013","journal-title":"Chest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jcf.2016.07.012","article-title":"Reduced survival in adult cystic fibrosis despite attenuated lung function decline","volume":"16","author":"Keating","year":"2017","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front. Pediatr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"B48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1164\/rccm.200407-948OC","article-title":"Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis","volume":"171","author":"Kraemer","year":"2005","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1164\/ajrccm.165.6.2104073","article-title":"Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children","volume":"165","author":"Lebecque","year":"2002","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"EFFECT OF ELEXACAFTOR\/TEZACAFTOR\/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS","volume":"22","author":"Lee","year":"2023","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jcf.2018.12.006","article-title":"A multicenter evaluation of sweat chloride concentration and variation in infants with cystic fibrosis","volume":"18","author":"LeGrys","year":"2019","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e20220312","DOI":"10.36416\/1806-3756\/e20220312","article-title":"Elexacaftor\/tezacaftor\/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study","volume":"49","author":"Lopes","year":"2023","journal-title":"J. Bras. Pneumol. publicacao Of. Soc. Bras. Pneumol. Tisilogia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFabd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: a Phase 3b, Randomized, Placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ppul.26318","article-title":"Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis","volume":"58","author":"McCoy","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","article-title":"Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype","volume":"14","author":"McKone","year":"2015","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"","journal-title":"New Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e220740","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw. open"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J. Clin. investigation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2003079","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O\u2019Shea","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1153656","DOI":"10.3389\/fphar.2023.1153656","article-title":"Differential effects of ELX\/TEZ\/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G","volume":"14","author":"Pallenberg","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1179208","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B69","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic fibrosis foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B70","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ppul.23227","article-title":"Decline in lung function does not predict future decline in lung function in cystic fibrosis patients","volume":"50","author":"Rosenfeld","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"Jama"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/ppul.25980","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: a 24-week observational study","volume":"57","author":"Salvatore","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/sim.1104","article-title":"Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients","volume":"21","author":"Schluchter","year":"2002","journal-title":"Statistics Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor - tezacaftor - Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"","journal-title":"Heliyon"},{"key":"B75","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"","journal-title":"Liver Int. official J. Int. Assoc. Study Liver"},{"key":"B76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B77","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jcf.2013.03.004","article-title":"The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation","volume":"12","author":"Seliger","year":"2013","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B78","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1183\/09059180.00008512","article-title":"Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation","volume":"22","author":"Sermet-Gaudelus","year":"2013","journal-title":"Eur. Respir. Rev. official J. Eur. Respir. Soc."},{"key":"B79","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B80","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet (London, Engl."},{"key":"B82","first-page":"1097","article-title":"Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation","volume":"17","author":"Snell","year":"1998","journal-title":"J. heart lung Transplant. official Publ. Int. Soc. Heart Transplant."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1164\/rccm.201606-1286ED","article-title":"Sweat chloride: the critical biomarker for cystic fibrosis trials","volume":"194","author":"Sontag","year":"2016","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"Cd010966","DOI":"10.1002\/14651858.CD010966.pub3","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane database Syst. Rev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"Cd010966","DOI":"10.1002\/14651858.CD010966.pub2","article-title":"Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis","volume":"8","author":"Southern","year":"2018","journal-title":"Cochrane database Syst. Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B87","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B88","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B89","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1164\/ajrccm\/151.3_Pt_1.899","article-title":"Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis","volume":"151","author":"Stewart","year":"1995","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B91","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcf.2013.07.003","article-title":"Relationship between sweat chloride, sodium, and age in clinically obtained samples","volume":"13","author":"Traeger","year":"2014","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ppul.24726","article-title":"Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007-2016","volume":"55","author":"Vandenbroucke","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jcf.2015.09.008","article-title":"Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B97","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jcf.2016.02.015","article-title":"Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations","volume":"16","author":"Vermeulen","year":"2017","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B98","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged \u2a7e6 Years with Cystic Fibrosis and at Least One F508del Allele: a Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMc1510466","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7812\/TPP\/21.089","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on hospitalizations and intravenous antibiotic use","volume":"26","author":"Walter","year":"2022","journal-title":"Perm. J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur. Respir. J."},{"key":"B102","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1159\/000524773","article-title":"Effect of triple combination CFTR modulator therapy on sleep in adult patients with cystic fibrosis","volume":"101","author":"Welsner","year":"2022","journal-title":"Respir. Int. Rev. Thorac. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/s0022-3476(95)70157-5","article-title":"Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations","volume":"127","author":"Wilschanski","year":"1995","journal-title":"J. Pediatr."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B105","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jpeds.2012.08.040","article-title":"Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis","volume":"162","author":"Yen","year":"2013","journal-title":"J. Pediatr."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur. Respir. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1275470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T08:32:52Z","timestamp":1702542772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1275470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":108,"alternative-id":["10.3389\/fphar.2023.1275470"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1275470","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"article-number":"1275470"}}